JP4129396B2 - 細胞の保存 - Google Patents
細胞の保存 Download PDFInfo
- Publication number
- JP4129396B2 JP4129396B2 JP2002550782A JP2002550782A JP4129396B2 JP 4129396 B2 JP4129396 B2 JP 4129396B2 JP 2002550782 A JP2002550782 A JP 2002550782A JP 2002550782 A JP2002550782 A JP 2002550782A JP 4129396 B2 JP4129396 B2 JP 4129396B2
- Authority
- JP
- Japan
- Prior art keywords
- gel
- cells
- gelatin
- hydrolyzed
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000004321 preservation Methods 0.000 title description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 260
- 239000000499 gel Substances 0.000 claims abstract description 252
- 108010010803 Gelatin Proteins 0.000 claims abstract description 238
- 239000008273 gelatin Substances 0.000 claims abstract description 237
- 229920000159 gelatin Polymers 0.000 claims abstract description 237
- 235000019322 gelatine Nutrition 0.000 claims abstract description 237
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 237
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 239000002609 medium Substances 0.000 claims description 43
- 238000003860 storage Methods 0.000 claims description 43
- 239000007787 solid Substances 0.000 claims description 42
- 238000010438 heat treatment Methods 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000006143 cell culture medium Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 230000010412 perfusion Effects 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000004114 suspension culture Methods 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 238000007711 solidification Methods 0.000 claims 1
- 230000008023 solidification Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 description 52
- 230000000694 effects Effects 0.000 description 16
- 210000000056 organ Anatomy 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 11
- 108010052832 Cytochromes Proteins 0.000 description 10
- 102000018832 Cytochromes Human genes 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 9
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 8
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 238000001243 protein synthesis Methods 0.000 description 8
- 210000005234 proximal tubule cell Anatomy 0.000 description 8
- 230000003915 cell function Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000005138 cryopreservation Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010044467 Isoenzymes Proteins 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000013382 Gelatinases Human genes 0.000 description 3
- 108010026132 Gelatinases Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 108010042606 Tyrosine transaminase Proteins 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002900 effect on cell Effects 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000009283 thermal hydrolysis Methods 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100025287 Cytochrome b Human genes 0.000 description 2
- 108010075028 Cytochromes b Proteins 0.000 description 2
- 108010007167 Cytochromes b5 Proteins 0.000 description 2
- 102000007605 Cytochromes b5 Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 101710159910 Movement protein Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 2
- 229960005263 bucladesine Drugs 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001120 cytoprotective effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000006391 Ion Pumps Human genes 0.000 description 1
- 108010083687 Ion Pumps Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000011994 cellular protein metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/128—Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gels; Chemically altering living parts, e.g. by cross-linking
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0031065.6A GB0031065D0 (en) | 2000-12-20 | 2000-12-20 | Preservation of cells |
| PCT/GB2001/005688 WO2002049428A1 (en) | 2000-12-20 | 2001-12-20 | Preservation of cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007278385A Division JP4243638B2 (ja) | 2000-12-20 | 2007-10-26 | 細胞の保存 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004516020A JP2004516020A (ja) | 2004-06-03 |
| JP2004516020A5 JP2004516020A5 (enExample) | 2006-12-21 |
| JP4129396B2 true JP4129396B2 (ja) | 2008-08-06 |
Family
ID=9905463
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002550782A Expired - Fee Related JP4129396B2 (ja) | 2000-12-20 | 2001-12-20 | 細胞の保存 |
| JP2007278385A Expired - Fee Related JP4243638B2 (ja) | 2000-12-20 | 2007-10-26 | 細胞の保存 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007278385A Expired - Fee Related JP4243638B2 (ja) | 2000-12-20 | 2007-10-26 | 細胞の保存 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040053207A1 (enExample) |
| EP (1) | EP1343369B1 (enExample) |
| JP (2) | JP4129396B2 (enExample) |
| KR (1) | KR100564813B1 (enExample) |
| AT (1) | ATE284140T1 (enExample) |
| AU (2) | AU1622302A (enExample) |
| CA (1) | CA2432123C (enExample) |
| DE (1) | DE60107718T8 (enExample) |
| DK (1) | DK1343369T3 (enExample) |
| ES (1) | ES2234771T3 (enExample) |
| GB (1) | GB0031065D0 (enExample) |
| NZ (1) | NZ526647A (enExample) |
| WO (1) | WO2002049428A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222093A1 (es) * | 2003-07-01 | 2005-01-16 | Advanced In Vitro Cell Technologies, S.L. | Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro. |
| CN100425693C (zh) * | 2004-02-16 | 2008-10-15 | 瑞德肝脏疾病研究(上海)有限公司 | 一种保存体外肝细胞系统的方法 |
| DE102007047040A1 (de) * | 2007-10-01 | 2009-04-16 | Fresenius Kabi Deutschland Gmbh | Transparentes Kältegel |
| JP5237714B2 (ja) * | 2008-07-29 | 2013-07-17 | ＢｉｏＲＯＩＳ株式会社 | 細胞輸送用担体及びそれを使用した細胞の輸送方法 |
| WO2012127224A1 (en) | 2011-03-21 | 2012-09-27 | University Of Reading | Transport of cells in hydrogels |
| DE102012110612A1 (de) * | 2012-11-06 | 2014-05-08 | Gelita Ag | Kollagenhydrolysat und dessen Verwendung |
| WO2015138832A1 (en) | 2014-03-13 | 2015-09-17 | The General Hospital Corporation | Devices and methods to improve and assess viability of human livers |
| EP3638019A4 (en) | 2017-06-14 | 2020-08-26 | The General Hospital Corporation | VERY LOW TEMPERATURE CRYOPRESERVATION |
| WO2019232268A1 (en) | 2018-05-30 | 2019-12-05 | Mustafa Korkut Uygun | Cryopreservation of tissues and organs |
| WO2021160919A1 (es) * | 2020-02-14 | 2021-08-19 | Readycell, S.L. | Sistema para el almacenamiento y transporte de líneas celulares |
| US20220145258A1 (en) | 2020-11-10 | 2022-05-12 | Vessl Therapeutics Ltd | Methods of preconditioning vascular cells for transduction, methods of transduction and methods of preserving transduced cells |
| JP2025535977A (ja) * | 2022-12-28 | 2025-10-30 | ルースロ ビーヴイ | コラーゲン加水分解物を含む凍結保存調製物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1635997A1 (ru) * | 1988-11-23 | 1991-03-23 | 1-Й Московский Медицинский Институт Им.И.М.Сеченова | Состав дл перфузии изолированного мозга млекопитающих |
| US4923797A (en) * | 1988-11-29 | 1990-05-08 | President & Fellows Of Harvard College | Stabilization of leukocytes |
| EP1002538A3 (en) * | 1992-06-25 | 2000-07-19 | SCHEER, David | Stem cell and lymphocyte storage |
| US5858783A (en) * | 1993-05-25 | 1999-01-12 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Production of normal mammalian organ culture using a medium containing mem-alpha, leibovitz L-15, glucose galactose fructose |
| JPH07255469A (ja) * | 1994-03-17 | 1995-10-09 | Kurabo Ind Ltd | 動物細胞の凍結保存液 |
| US5635344A (en) * | 1994-12-07 | 1997-06-03 | Cedra Corp. | Shipping medium for organ-derived cells |
| FR2746109B1 (fr) * | 1996-03-12 | 1998-04-17 | Rhone Poulenc Rorer Sa | Milieu pour la conservation de materiel biologique |
| US6992172B1 (en) * | 1999-11-12 | 2006-01-31 | Fibrogen, Inc. | Recombinant gelatins |
-
2000
- 2000-12-20 GB GBGB0031065.6A patent/GB0031065D0/en not_active Ceased
-
2001
- 2001-06-27 US US10/451,272 patent/US20040053207A1/en not_active Abandoned
- 2001-12-20 JP JP2002550782A patent/JP4129396B2/ja not_active Expired - Fee Related
- 2001-12-20 ES ES01271146T patent/ES2234771T3/es not_active Expired - Lifetime
- 2001-12-20 DE DE60107718T patent/DE60107718T8/de active Active
- 2001-12-20 NZ NZ526647A patent/NZ526647A/en unknown
- 2001-12-20 DK DK01271146T patent/DK1343369T3/da active
- 2001-12-20 EP EP01271146A patent/EP1343369B1/en not_active Expired - Lifetime
- 2001-12-20 WO PCT/GB2001/005688 patent/WO2002049428A1/en not_active Ceased
- 2001-12-20 AT AT01271146T patent/ATE284140T1/de not_active IP Right Cessation
- 2001-12-20 AU AU1622302A patent/AU1622302A/xx active Pending
- 2001-12-20 KR KR1020037008192A patent/KR100564813B1/ko not_active Expired - Fee Related
- 2001-12-20 CA CA002432123A patent/CA2432123C/en not_active Expired - Fee Related
- 2001-12-20 AU AU2002216223A patent/AU2002216223B2/en not_active Ceased
-
2007
- 2007-10-26 JP JP2007278385A patent/JP4243638B2/ja not_active Expired - Fee Related
-
2008
- 2008-09-05 US US12/204,955 patent/US20090042289A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002049428A1 (en) | 2002-06-27 |
| AU2002216223B2 (en) | 2005-05-19 |
| CA2432123C (en) | 2005-07-12 |
| KR100564813B1 (ko) | 2006-03-27 |
| DK1343369T3 (da) | 2005-02-14 |
| EP1343369A1 (en) | 2003-09-17 |
| DE60107718T2 (de) | 2005-12-01 |
| DE60107718D1 (de) | 2005-01-13 |
| KR20030094224A (ko) | 2003-12-11 |
| ES2234771T3 (es) | 2005-07-01 |
| JP2008073054A (ja) | 2008-04-03 |
| ATE284140T1 (de) | 2004-12-15 |
| CA2432123A1 (en) | 2002-06-27 |
| US20040053207A1 (en) | 2004-03-18 |
| AU1622302A (en) | 2002-07-01 |
| NZ526647A (en) | 2004-06-25 |
| GB0031065D0 (en) | 2001-01-31 |
| DE60107718T8 (de) | 2006-05-18 |
| JP2004516020A (ja) | 2004-06-03 |
| EP1343369B1 (en) | 2004-12-08 |
| US20090042289A1 (en) | 2009-02-12 |
| JP4243638B2 (ja) | 2009-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4243638B2 (ja) | 細胞の保存 | |
| DK2048228T3 (en) | Human liver progenitors | |
| Koebe et al. | A new approach to the cryopreservation of hepatocytes in a sandwich culture configuration | |
| Koebe et al. | Cryopreserved porcine hepatocyte cultures | |
| JP2008539697A (ja) | 新規な細胞組成物およびその調製方法 | |
| Ogoke et al. | Bioengineering considerations in liver regenerative medicine | |
| Lloyd et al. | Cryopreservation of hepatocytes: a review of current methods for banking | |
| Chen et al. | Long-term culture of hepatocytes from human adults | |
| Yoffe et al. | Cultures of human liver cells in simulated microgravity environment | |
| Son et al. | Optimization of cryoprotectants for cryopreservation of rat hepatocyte | |
| Guillouzo et al. | Human hepatocyte cultures: a model of pharmacotoxicological studies | |
| Bayliss et al. | Isolation and culture of human hepatocytes | |
| Ehashi et al. | Oncostatin M stimulates proliferation and functions of mouse fetal liver cells in three‐dimensional cultures | |
| Magalhaes et al. | The use of vitrification to preserve primary rat hepatocyte monolayer on collagen-coated poly (ethylene-terephthalate) surfaces for a hybrid liver support system | |
| CN101312648A (zh) | 肝实质细胞的冷冻保存 | |
| WO1998035021A1 (en) | Preparation of spheroids and their use in medicin or diagnosis | |
| Evans | Hypothermic preservation of hepatocytes on gelatin gels | |
| Poole et al. | Preparation and properties of primary maintenance cultures of adult rabbit hepatocytes | |
| Guibert et al. | Hypothermic storage of periportal and perivenous rat hepatocytes | |
| Evans | Maintenance of cytochrome P-450 levels in hepatocytes preserved on gelatin gels | |
| Evans | Preservation and transportation of hepatocyte monolayers in a no spill format at non freezing temperatures | |
| JPH01296982A (ja) | 肝細胞の培養方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040908 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040908 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061101 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20061101 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20061120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061128 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070528 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070626 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070925 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071026 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080312 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080325 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080422 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080519 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110523 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110523 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120523 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130523 Year of fee payment: 5 |
|
| LAPS | Cancellation because of no payment of annual fees |